spacer
home > ebr > winter 2018 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

This edition of EBR went to press just as a major breakthrough in the development of a potential treatment for Huntington’s disease was announced by researchers at University College London. Identifying, isolating and then being able to block synthesis of the defective, toxic proteins responsible for disease pathology has taken decades to accomplish, and a number of articles in our current issue resonate with aspects of this journey from gene to treatment. Although the exact neurological role of the Huntingtin gene product is not yet known, it is a complex, highly polymorphic protein and has the ability to identify even subtle changes from a core range of sequences, and structures of biological relevance through functional approaches such as microarrays could become increasingly valuable tools in disease research. The faulty Huntingtin gene responsible for Huntington’s disease was discovered in 1993.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Change of Company Name: VTU Technology is now VALIDOGEN

VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement